Sotatercept is a recombinant activin receptor type IIA-Fc fusion protein indicated for the treatment of adults with pulmonary arterial hypertension (PAH). By acting as a ligand trap for TGF-beta superfamily… Read more
Sotatercept is a recombinant activin receptor type IIA-Fc fusion protein indicated for the treatment of adults with pulmonary arterial hypertension (PAH). By acting as a ligand trap for TGF-beta superfamily ligands, this therapy modulates signaling pathways involved in vascular remodeling to reduce pulmonary arterial pressure. This category provides essential reference standards for the sotatercept drug substance, alongside its related compounds, such as impurities and metabolites, which are critical for robust analytical testing. Pharmaceutical laboratories rely on these high-quality materials for impurity profiling, method validation, and ongoing quality control of the API. The collection also includes stable isotope labelled versions of these compounds, which serve as internal standards for sensitive bioanalytical assays. Utilizing these characterized reference materials ensures the accuracy, reproducibility, and regulatory compliance of testing procedures throughout the pharmaceutical development and manufacturing lifecycle.